Impact on Medical Care Expenditures of Individuals Progressing from Prediabetes to Diabetes
The results find individuals with pre-DM later diagnosed with DM have medical care expenditures nearly one-third greater compared to their counterparts (p<0.05). Individuals diagnosed with DM had on average $2,800 more in medical care expenditures.
For employers with 1,000 employees with similar risk factors to those examined, implementation of a DPP would cost roughly $450 per employee and save 28 individuals from becoming diabetic. Net savings over three years for this population would be approximately $150,000 in direct medical spending, translating to roughly $225 monthly per member. Based on this, ROI over three years in a DPP for these employers would be 182%. Overall net savings and ROI would be higher when including longer term trends and savings from lost productivity, suggesting that investments in DPP are worthwhile in the long run.
Learning Areas:Planning of health education strategies, interventions, and programs
Public health or related public policy
Describe the progression of medical care expenditures among individuals with prediabetes (pre-DM). Compare expenditures between individuals who are later diagnosed with diabetes relative to those who do not progress to diabetes. Assess the potential savings and return on investments associated with participation in evidence based Diabetes Prevention Programs.
Keyword(s): Diabetes, Economic Analysis
Qualified on the content I am responsible for because: I am a Senior Economist for the American Medical Association's 'Improving Health Outcomes' team. My research focuses on economic studies of costs associated with diseases impacting a large percentage of the US population, physician and patient behaviors impact on outcomes and cost of care, and development of evaluation protocols to asses the impact of the team's initiatives.
Any relevant financial relationships? No
I agree to comply with the American Public Health Association Conflict of Interest and Commercial Support Guidelines, and to disclose to the participants any off-label or experimental uses of a commercial product or service discussed in my presentation.